资讯

NRx Pharmaceuticals outlines expanded fast track for NRX-100 and targets $750M ketamine ...

Q2 2025 Management View Jonathan C. Javitt, Co-Founder, Chief Scientist Officer, Chairman & Interim CEO, highlighted that NRx Pharmaceuticals is advancing three drug approval applications and the ...